The FDA Approved Treatment for Sickle Cell Disease
Last month, the FDA approved the first cell-based therapies for the treatment of Sickle cell disease in patients 12 years of age and older: CASGEVY and LYFGENIA. Casgevy is the first FDA-approved treatment to utilize a novel type of genome editing technology that modifies the patients hematopoietic (blood) stem cells. The modified blood stem cells…